Skip to main content

Combination strategies

Section edited by Paolo A. Ascierto

This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.

Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may en to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

Featured articles

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
Takashi Shingu, et al


Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Jenny E Hernandez-Davies, et al


What’s new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola and Michael B Atkins

Page 3 of 3

  1. Out of hospital cardiac arrest (OHCA) has a poor outcome. Recent non-randomized studies of ECLS (extracorporeal life support) in OHCA suggested further prospective multicenter studies to define population that...

    Authors: Jan Belohlavek, Karel Kucera, Jiri Jarkovsky, Ondrej Franek, Milana Pokorna, Jiri Danda, Roman Skripsky, Vit Kandrnal, Martin Balik, Jan Kunstyr, Jan Horak, Ondrej Smid, Jaroslav Valasek, Vratislav Mrazek, Zdenek Schwarz and Ales Linhart

    Citation: Journal of Translational Medicine 2012 10:163

    Content type: Protocol

    Published on:

  2. P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clinical trials. Gemcitabine is a standard of care for the treatment of pancreatic cancer. The present study investigated the effect o...

    Authors: Maggie J Rathos, Kavita Joshi, Harshal Khanwalkar, Sonal M Manohar and Kalpana S Joshi

    Citation: Journal of Translational Medicine 2012 10:161

    Content type: Research

    Published on:

  3. Previous studies have shown that long-term oral daily PDE 5 inhibitors (PDE5i) counteract fibrosis, cell loss, and the resulting dysfunction in tissues of various rat organs and that implantation of skeletal m...

    Authors: Judy SC Wang, Istvan Kovanecz, Dolores Vernet, Gaby Nolazco, George E Kopchok, Sheryl L Chow, Rodney A White and Nestor F Gonzalez-Cadavid

    Citation: Journal of Translational Medicine 2012 10:159

    Content type: Research

    Published on:

  4. Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clini...

    Authors: Wenshi Wang, Daohai Yu, Amod A Sarnaik, Bin Yu, Maclean Hall, Dawn Morelli, Yonghong Zhang, Xiuhua Zhao and Jeffrey S Weber

    Citation: Journal of Translational Medicine 2012 10:146

    Content type: Research

    Published on:

  5. After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunizat...

    Authors: Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, Mark B Faries, Soldano Ferrone, Keith Flaherty, Bernard A Fox, Thomas F Gajewski, Jeffrey E Gershenwald, Helen Gogas, Kenneth Grossmann, Axel Hauschild, F Stephen Hodi, Richard Kefford, John M Kirkwood, Sancy Leachmann…

    Citation: Journal of Translational Medicine 2012 10:83

    Content type: Meeting report

    Published on:

  6. Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth, immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30–100 nm membra...

    Authors: Annette M Marleau, Chien-Shing Chen, James A Joyce and Richard H Tullis

    Citation: Journal of Translational Medicine 2012 10:134

    Content type: Review

    Published on:

  7. Adeno-associated vectors (rAAV) have been used to attain long-term liver gene expression. In humans, the cellular immune response poses a serious obstacle for transgene persistence while neutralizing humoral i...

    Authors: Carmen Unzu, Sandra Hervás-Stubbs, Ana Sampedro, Itsaso Mauleón, Uxua Mancheño, Carlos Alfaro, Rafael Enríquez de Salamanca, Alberto Benito, Stuart G Beattie, Harald Petry, Jesús Prieto, Ignacio Melero and Antonio Fontanellas

    Citation: Journal of Translational Medicine 2012 10:122

    Content type: Research

    Published on:

  8. At recurrence the use of nitrosoureas is widely-used as a therapeutic option for glioblastoma (GBM) patients. The efficacy of fotemustine (FTM) has been demonstrated in phase II clinical trials; however, these...

    Authors: Alessandro Paccapelo, Ivan Lolli, Maria Grazia Fabrini, Giovanni Silvano, Beatrice Detti, Franco Perrone, Giuseppina Savio, Matteo Santoni, Erminio Bonizzoni, Tania Perrone and Silvia Scoccianti

    Citation: Journal of Translational Medicine 2012 10:90

    Content type: Research

    Published on:

  9. Clinical observations suggested that a non negligible proportion of patients, ranging from 40% to 70%, does not seem to benefit from the use of anti-EGFR targeted antibodies even in the absence of a mutation o...

    Authors: Mario Scartozzi, Riccardo Giampieri, Elena Maccaroni, Alessandra Mandolesi, Simona Biagetti, Simona Alfonsi, Lucio Giustini, Cristian Loretelli, Luca Faloppi, Alessandro Bittoni, Maristella Bianconi, Michela Del Prete, Italo Bearzi and Stefano Cascinu

    Citation: Journal of Translational Medicine 2012 10:71

    Content type: Research

    Published on:

  10. The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors h...

    Authors: Gabriele Madonna, Claudio Dansky Ullman, Giusy Gentilcore, Giuseppe Palmieri and Paolo Antonio Ascierto

    Citation: Journal of Translational Medicine 2012 10:53

    Content type: Review

    Published on:

  11. The aim of the present study was to analyse the expression of Secreted protein acidic and rich in cysteine (SPARC) in nasopharyngeal carcinoma (NPC) specimens, and to evaluate its correlation with clinicopatho...

    Authors: Hai-Yun Wang, Yang-Yang Li, Qiong Shao, Jing-Hui Hou, Fang Wang, Man-Bo Cai, Yi-Xin Zeng and Jian-Yong Shao

    Citation: Journal of Translational Medicine 2012 10:27

    Content type: Research

    Published on:

  12. Shuanglong formula (SLF), a Chinese medicine composed of panax ginseng and salvia miltiorrhiza exhibited significant effect in the treatment of myocardial infarction (MI) in clinical. Because of the complex natur...

    Authors: Qiong-Lin Liang, Xiao-Ping Liang, Yi-Ming Wang, Yuan-Yuan Xie, Rong-Li Zhang, Xi Chen, Rong Gao, Yi-Jun Cheng, Jun Wu, Qing-Bo Xu, Qing-Zhong Xiao, Xue Li, Shu-Feng Lv, Xue-Mei Fan, Hong-Yang Zhang, Qing-Li Zhang…

    Citation: Journal of Translational Medicine 2012 10:26

    Content type: Research

    Published on:

  13. Copper export protein ATP7A is important for maintaining copper homeostasis. Recent studies have shown that copper transporters are also involved in the transport of platinum. The goal of this study was to det...

    Authors: Zhuang-hua Li, Miao-zhen Qiu, Zhao-lei Zeng, Hui-yan Luo, Wen-jing Wu, Feng Wang, Zhi-qiang Wang, Dong-sheng Zhang, Yu-hong Li and Rui-hua Xu

    Citation: Journal of Translational Medicine 2012 10:21

    Content type: Research

    Published on:

  14. HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively eva...

    Authors: George Fountzilas, Christos Valavanis, Vassiliki Kotoula, Anastasia G Eleftheraki, Konstantine T Kalogeras, Olympia Tzaida, Anna Batistatou, Ralf Kronenwett, Ralph M Wirtz, Mattheos Bobos, Eleni Timotheadou, Nikolaos Soupos, George Pentheroudakis, Helen Gogas, Dimitrios Vlachodimitropoulos, Genovefa Polychronidou…

    Citation: Journal of Translational Medicine 2012 10:10

    Content type: Research

    Published on:

  15. Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic.

    Authors: Julia B Sturm, Michael Hess, Stephanie Weibel, Nanhai G Chen, Yong A Yu, Qian Zhang, Ulrike Donat, Cora Reiss, Stepan Gambaryan, Georg Krohne, Jochen Stritzker and Aladar A Szalay

    Citation: Journal of Translational Medicine 2012 10:9

    Content type: Research

    Published on:

  16. Cancer patients receiving chemotherapy are at increased risk of thrombosis. Nadroparin has been demonstrated to reduce the incidence of venous and arterial thrombotic events (TEs) by about 50% in cancer outpat...

    Authors: Sandro Barni, Roberto Labianca, Giancarlo Agnelli, Erminio Bonizzoni, Melina Verso, Mario Mandalà, Matteo Brighenti, Fausto Petrelli, Carlo Bianchini, Tania Perrone and Giampietro Gasparini

    Citation: Journal of Translational Medicine 2011 9:179

    Content type: Protocol

    Published on:

  17. Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compar...

    Authors: Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori and Wainer Zoli

    Citation: Journal of Translational Medicine 2011 9:94

    Content type: Research

    Published on:

Annual Journal Metrics